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Plasmacytoid dendritic cells (pDCs) in the periphery of subjects with human immunodefi-
ciency virus (HIV)/acquired immunodeficiency syndrome (AIDS) decrease over time, and
the fate of these cells has been the subject of ongoing investigation. Previous studies
using animal models as well as studies with humans suggest that these cells may
redistribute to the gut. Other studies using animal models propose that the periphery
pDCs are depleted and gut is repopulated with naive pDCs from the bone marrow. In
the present study, we utilized immunohistochemistry to survey duodenum biopsies of
subjects with HIV/AIDS and controls. We observed that subjects with HIV/AIDS had
increased infiltration of Ki-67+/CD303+ pDCs, a phenotype consistent with bone mar-
row-derived pre-pDCs. In contrast, Ki-67+/CD303+ pDCs were not observed in control
biopsies. We additionally observed that gut-associated pDCs in HIV/AIDS cases upreg-
ulate the proapoptotic enzyme granzyme B; however, no granzyme B was observed in
the pDCs of control biopsies. Our data are consistent with reports in animal models that
suggest periphery pDCs are depleted by exhaustion and that naive pDCs egress from
the bone marrow and ultimately infiltrate the gut mucosa. Additionally, our observation
of granzyme B upregulation in naive pDCs may identify a contributing factor to the gut
pathology associated with HIV infection.
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introduction
Human immunodeficiency virus (HIV) infection is character-
ized by a rapid loss of peripheral CD4+ T lymphocytes during 
the acute phase (1, 2). CD4+ T-cell levels partially recover after 
this phase; however, they gradually decline as the infection pro-
gresses, ultimately contributing to the development of acquired 
immunodeficiency syndrome (AIDS). In order to establish an 
infection, the viral GP120 envelope glycoprotein must bind to the 
cell’s primary CD4 receptor as well as a coreceptor, either CCR5 
or CXCR4 (3, 4). In addition to T cells, macrophages and den-
dritic cells also express these receptors and are thus susceptible to 
HIV infection (5, 6). It is therefore not surprising that decreased 
numbers of dendritic cells are observed in the blood of HIV cases 
and their presence inversely correlate with plasma viral load. 
For example, Grassi and coworkers reported that conventional 
dendritic cells (cDCs) expressing the integrin CD11c showed a 
significant decline during the course of HIV infection and did not 
return to normal levels after highly active antiretroviral therapy 
(HAART)  (7). Loss of cDCs as well as plasmacytoid dendritic 
cells (pDCs) during HIV infection was also reported by Donaghy 
et al. (8) and similar observations were described by Pacanowski 
coworkers (9). Consistent with these observations, Azzoni et al. 
reported that cDC and pDC levels were lower in HIV viremic 
children when compared with those with undetectable plasma 
viral load (10). In the same study, they showed that subjects with 
declining levels of CD4+ T cells are more likely to present with 
lower DC numbers when compared with those with a stable 
CD4+ T cell population. These data support a characteristic 
pathology of HIV infection where declining DC levels inversely 
correlate with plasma viral load and further suggest that DCs play 
an important role in HIV pathogenesis.
Plasmacytoid DCs are the primary source of type I IFN and 
account for over 95% of all IFNα produced by circulating lym-
phocytes (11). Through the inhibition of viral replication, IFNα 
would likely play a central role in controlling HIV replication and 
consistent with this supposition, previous studies have reported 
that high levels of serum IFNα are often found in asymptomatic 
HIV carriers (12). In contrast, severe cases of AIDS have been 
associated with a diminished capacity to produce IFNα and the 
development of opportunistic infections (13). Furthermore, 
decreased IFNα levels are reported to correlate with lower cir-
culating pDC numbers (14). Collectively, these data suggest that 
a decline in circulating pDCs and/or a diminished functional 
capacity is associated with the lower serum IFNα levels observed 
in subjects with HIV/AIDS.
A decline in peripheral pDCs during the course of HIV infec-
tion is well documented; however, the mechanism responsible 
for this decline remains a matter of current investigation. In vitro 
studies have shown that pDCs are susceptible to HIV infection 
and readily support viral replication (15). For this reason, their 
decline has been suggested to be the result of cytopathic viral 
replication (16). It has also been proposed that this decline 
may be the result of redistribution into the tissue, such as the 
regional lymph nodes (17, 18). Indeed, pDC redistribution into 
the lymph nodes has been observed in the early stages of sim-
ian immune deficiency virus (SIV) infection, the animal model 
for human HIV infection (17, 19, 20). Nevertheless, depletion 
of pDCs in lymphoid nodes of subjects infected with HIV has 
been documented (21), suggesting that the potential site of 
pDC redistribution remains elsewhere. Recently, Lehmann and 
colleagues observed pDC accumulation into the gut mucosa 
of HIV-infected subjects (22). Consistent with observations 
in SIV-infected macaques, pDCs in HIV cases increased their 
expression of gut-homing receptors (6, 23), implying that deple-
tion of circulating pDCs is likely a result of their redistribution. 
However, a recent report by Bruel et al. suggests that the loss of 
pDCs in the periphery is the result of pDC exhaustion and the 
apparent redistribution of pDCs to the gut can be explained as 
pDC precursors migrating from the bone marrow to the gut (24). 
In a follow-up study to an early report (23), Li et  al. observed 
that, in acute SIV infection of rhesus macaques, gut-homing was 
imprinted upon pDCs in the bone marrow, which resulted in a 
decline in pDCs from circulation and secondary lymphoid tissue 
and subsequent accumulation of hyperfunctional CD4+ pDCs in 
the mucosae (25).
In the present study, we have investigated the distribution 
and phenotype of pDCs in human subjects with HIV/AIDS. 
Consistent with previous reports, our data show a statistically 
significant decline in circulating pDCs in cases when compared 
with healthy controls. Using immunohistochemistry, we also 
observed a significant increase of pDC infiltration into the duo-
denal mucosal tissue of HIV cases when compared with control 
biopsies. Additionally and consistent with observations made by 
Bruel et al. in SIV-infected cynomolgus macaques, we observed 
that duodenal-associated pDCs in HIV-positive subjects express 
the cellular proliferation marker Ki-67. Our study supports the 
previous report of Bruel et al. (24) and Li et al. (25); however, fur-
ther studies will be required to fully appreciate the contribution of 
this subpopulation of pDCs to the enteropathy of HIV infection.
Materials and Methods
subjects
Twenty-three subjects (15 males and 8 females) who were hos-
pitalized at the Republican Center for AIDS Prophylaxis and 
Prevention, Republic of Tatarstan, were enrolled in this study. 
Diagnosis of HIV infection was established based on the presence 
of anti-HIV antibodies using ELISA and confirmed by Western 
blot. Blood samples were collected from the 23 HIV cases and 
six of these subjects consented to providing a duodenal biopsy 
for analysis. Additionally, blood samples were collected from 
16 healthy donors. For control biopsies, we utilized duodenal 
biopsies from eight individuals who underwent routine gastros-
copy for gastritis and were otherwise healthy. The Institutional 
Review Board of the Kazan Federal University approved this 
study and informed consent was obtained from each study 
subject according to the guidelines approved under this protocol 
(article 20, Federal Law “Protection of Health Right of Citizens 
of Russian Federation” N323-FZ, 11.21.2011) and in accord with 
the Declaration of Helsinki (2008). Surplus clinical biopsies from 
subjects with gastritis were acquired under an exemption to 
IRB as determined by the University of Nevada, Reno Office of 
Research Integrity (exemption #508962-1).
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clinical Presentation of hiV cases
Diagnosis of HIV infection was established by detection of anti-
HIV antibodies by ELISA and confirmed by Western blot. A total 
of 23 HIV cases were enrolled in this study (Table 1); eight of whom 
were female (35%) and 15 (65%) were male with an average age of 
35.6 years (range, 21–46 years). Mode of transmission included 
sexual contact (11 cases; 48%) and IV drug users (12 cases; 52%). 
Enrolled were 12 cases with the severe form (52%), 3 cases with 
the advanced form (13%), 4 cases with the mild form (17.5%), and 
4 cases with non-significant form (17.5%). Sixteen cases (70%) 
received antiviral treatment while seven cases (30%) remained 
without virus-specific therapy. Antiviral treatment included 
nucleoside analogs, non-nucleoside reverse transcriptase inhibi-
tors, and protease inhibitors. Average HIV RNA viral load was 
4412.1 ± 342 copies/ml, where 16 cases (70%) had a viral load 
higher than 250 copies/ml; the remaining seven cases (30%) had 
an undetectable viral load or less than 250 copies/ml. The mean 
CD4+ T-cell count was 306.1 ±  56 cells/mm3. As the disease 
progressed, some subjects were diagnosed with opportunistic 
infections, among which were candidiasis, hairy leukoplakia, and 
tuberculosis. HIV case characteristics and status are summarized 
in Table 1 and Table S1 in Supplementary Material.
antibodies for Flow cytometry and 
immunohistochemistry
PerCP mouse anti-human CD45 was from Beckman Coulter 
(Brea, CA, USA). PE Anti-Ki-67 (clone B56) and PE mouse IgG1,κ 
isotype control were from BD Pharmigen (San Jose, CA, USA); 
PE mouse anti-human GZMB IgG1 (clone GB11) and PE mouse 
IgG1 isotype control were from Life Technologies (Carlsbad, CA, 
USA). FITC or APC mouse anti-human CD303 (clone AC144); 
PE mouse anti-human CD123 (clone AC145); PE mouse anti-
human CD80 (clone 2D10); PE mouse anti-human CD56 IgG1 
(clone AF12-7H3); APC mouse anti-human CD11c IgG2b 
(clone MJ4-27G12); APC mouse IgG2b isotype control; and PE 
mouse anti-human CD4 (clone VIT4) were from MiltenyiBiotec 
(Auburn, CA, USA).
Flow cytometry analysis
Anticoagulated blood was collected in EDTA-containing vacu-
tainer tubes by venipuncture. Whole blood (100 μl) was labeled 
with anti-human CD45-PerCP, anti-human CD303-APC, and 
anti-human CD123-PE for 20  min at room temperature, lysed 
with FACS Lyse (BD Biosciences, San Jose, CA, USA), and 
analyzed immediately on a FACS Canto II flow cytometer using 
TaBle 1 | Demographics of hiV cases by World health Organization 
(WhO) immunological classification.
WhO hiV-associated 
immunological 
classification
cD4 (cells/
mm3)
sex Total
Male Female n %
Severe <200 8 4 12 52.0
Advanced 200–349 3 0 3 13.0
Mild 350–499 1 3 4 17.5
None/not significant ≥500 3 1 4 17.5
Total 15 (65%) 8 (35%) 23 100
FACS Diva software (BD Biosciences). A minimum of 300,000 
events was collected for each sample and pDCs were identified as 
being CD45+CD303+CD123+.
Tissues Preparation and immunohistochemical 
analysis
Limitations on gut tissue samples made flow cytometery analysis 
impractical; therefore, we characterized duodenum biopsies 
by immunohistochemistry. Fresh tissues were fixed in 4% 
paraformaldehyde for 4 h at 4°C and cryoprotected with a 30% 
sucrose solution in phosphate-buffered saline (PBS) before being 
paraffin embedded. Immunohistochemical (IHC) staining was 
performed on 2–3-μm-thick tissue sections. Tissue slides were 
deparaffinized with xylene and rehydrated through a graded 
alcohol series. Antigen retrieval was carried out by boiling 
slides in sodium citrate (0.01M, pH 6.0) at 95°C for 10 min. The 
slides were next rinsed in PBS and incubated in cold methanol 
for 20 min at −20°C. Tissue sections were then incubated with 
human AB serum to block non-specific staining (1  h at 37°C) 
and then incubated with the labeled antibody overnight at 4°C 
in a humidified chamber. Slides were then washed (3×; Tween 
0.1% PBS) and examined using a Leitz TCS-SP2 RS scanning 
laser confocal microscope (Wetzlar, Germany) and images were 
captured with Leitz analysis software.
In order to identify duodenum-infiltrating pDCs, we utilized a 
panel of fluorescently labeled monoclonal antibodies specific for 
putative surface cell receptors know to be expressed on mature and 
naive pDCs. Included in this panel were monoclonal antibodies 
specific for CD123, which is normally expressed on all mature 
and BM-derived pre-pDCs; CD303, which is uniquely expressed 
on circulating pDCs (26) and also on BM-derived pre-pDCs as 
early as Stage II (27); Ki-67, to distinguish naive pDCs (Ki-67+) 
from mature non-dividing (Ki-67−) pDCs; and the costimulatory 
marker, CD80, which is not expressed on BM-derived pre-pDCs 
at any stage, was used as an activation marker. We additionally 
probed our biopsies for the myloid CD marker, CD11c, which 
is also expressed on a minor population of BM-derived pDCs, 
and finally, in order to identify pDCs with cytotoxic potential, 
we probed our specimens for granzyme B (GZMB), and CD56.
statistical analysis
Data are presented as mean/SD. Statistical analysis was performed 
using Mann–Whitney test for comparisons between individual 
experimental groups (case and control). Significance was estab-
lished at a value of p < 0.05.
results
Decreased pDcs in the Periphery of  
hiV/aiDs case
Previous studies have shown that subjects with HIV/AIDS 
have decreased circulating pDCs when compared with healthy 
controls. To confirm that our study population was consistent 
with those previously reported, we initially evaluated our sub-
jects for circulating pDCs by flow cytometry. Total lymphocytes 
were first gated by CD45+/side scatter (data not shown) and 
then pDCs were identified as a population of CD303+/CD123+ 
FigUre 2 | infiltration of plasmacytoid dendritic cells in duodenum biopsies of six subjects with hiV/aiDs (a–F) and six non-hiV subjects who were 
evaluated for gastritis (g–l). Biopsies were probed with antibodies FITC-anti-CD303 monoclonal antibody (green) and nucleus localization was determined by 
TOPO3 staining (blue). Bar represents 20 μm.
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lymphocytes (Figure 1A). The mean pDC count was calculated as 
a ratio of CD303+CD123+CD45+ over total CD45+ lymphocytes. 
Consistent with the observations of others, we observe that, on 
average, subjects with HIV/AIDS had significantly lower circulat-
ing CD303+CD123+ lymphocytes when compared with healthy 
controls, 0.044 ± 0.084 vs. 0.093 ± 0.014 (p = 0.0031) (Figure 1B).
increased pDc infiltration of the Duodenum in 
association with hiV infection
Plasmacytoid dendritic cells exclusively express the surface marker 
CD303 (BDCA-2) and non-exclusively express CD123, the receptor 
for the myeloid stimulatory cytokine IL-3 (26, 28, 29). Consistent 
FigUre 1 | (a) Flow cytometry was used to evaluate circulating plasmacytoid dendritic cells (pDCs) in HIV/AIDS cases and controls. Aliquots of whole blood from 
23 cases and 16 controls were labeled with APC-anti-CD303, PE-anti-CD123, and PerCp-anti-CD45. Lymphocytes were initially gated by CD45+/side scatter and 
pDCs were identified as CD303+/CD123+ lymphocytes. (B) pDCs, as a percentage of total lymphocytes, were used to evaluate differences between cases and 
controls. Mean pDC counts of HIV cases were 0.044 ± 0.084 and controls were 0.093 ± 0.014 (p = 0.0031).
with ability to become infected by HIV, they also express the HIV 
receptor CD4 as well as the coreceptors CCR5 and CXCR4. As with 
other antigen-presenting cells, when activated, they additionally 
express the B7 costimulatory molecules CD80 and CD86. Therefore, 
in order to characterize gut-associated pDCs in HIV/AIDS cases 
and controls, we probed the respective duodenum biopsies with 
fluorescently labeled anti-CD303, anti-CD123, anti-CD4, and 
anti-CD80 monoclonal antibodies (30). Consistent with previous 
reports, we observed a substantial infiltration of CD303+ pDCs in 
all duodenum biopsies from the HIV-infected subjects; however, 
we observed significantly fewer infiltrating pDCs in the control 
biopsies (Figure  2). In order to quantify these differences, five 
TaBle 2 | Quantitative analysis of plasmacytoid dendritic cells (pDcs).
Field controls Mean/sD
1 2 3 4 5 6
1 1 1 2 3 1 2
2 3 2 4 3 0 4
3 0 5 1 1 3 2
4 1 1 0 3 2 5
5 1 1 2 1 2 2
Sum 6 10 9 11 8 15 9.8/3.1
Field hiV cases Mean/sD
1 2 3 4 5 6
1 10 12 15 9 9 18
2 12 7 14 15 14 18
3 16 12 17 10 17 10
4 10 15 10 13 11 13
5 11 11 7 17 13 11
Sum 59 57 63 64 64 70 61.4/4.5
Five microscopic fields were chosen at random and used to count total pDCs in the 
duodenum of six controls (top) and six cases (bottom). p = 0.0051 by Mann–Whitney.
FigUre 3 | Duodenum biopsies of hiV/aiDs cases and controls evaluated for coexpression of cD303 (green) and cD4 (red). Bar represents 20 μm. 
(a) HIV case duodenum biopsies probed with a monoclonal FITC-anti-CD303 antibody. (B) HIV case duodenum biopsies probed with a monoclonal PE-anti-CD4 
antibody. (c) HIV case duodenum biopsies DIC image merged with (a,B). (D) Control duodenum biopsies probed with a monoclonal FITC-anti-CD303 antibody. 
(e) Control duodenum biopsies probed with a monoclonal PE-anti-CD4 antibody. (F) Control duodenum biopsies DIC image merged with (D,e).
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microscopic fields were randomly chosen for each subjects in each 
cohort and used to calculated average pDC infiltration (Table 2). 
We observed a sixfold greater infiltration of pDCs in the gut biop-
sies of HIV-infected cases over that of the controls (p < 0.0051). 
In order to further characterize the pDC infiltrate, double staining 
was conducted which confirmed that all CD303+ cells were also 
all CD4+ consistent with peripheral and pDCs and state II and III 
BM-derived pDCs (Figure 3). Additionally, all CD303+ cells were 
also CD123+ in the control biopsies (Figures  4A–C); however 
and unexpectedly, the CD123 staining was observably lower or 
absent for the HIV cohort (Figures 4D–F). Finally, double staining 
for CD303 and CD80 revealed that most of the CD303+ cells in 
the control biopsies also expressed the activation marker CD80 
(Figures  4G–I), and all CD303+ cells in biopsies from the HIV 
cohort were also CD80+ (Figures 4J–L).
gut-associated pDcs in hiV cases Display an 
immature Phenotype
Using SIV-infected cynomolgus macaques, an animal model of 
HIV, Bruel and coworkers observed that gut-associated pDCs 
express the cellular proliferation marker Ki-67 (24). In that pDCs 
in the periphery do not divide, this observation suggests that the 
gut-associated pDCs in the SIV-infected macaques are pDCs 
precursors from bone marrow and not mature pDCs from the 
periphery. To the best of our knowledge, this observation has 
not been confirmed in humans. Therefore, we used fluorescently 
labeled anti-Ki-67 monoclonal antibodies to probe the biopsies of 
HIV-infected cases and controls. Consistent with the observations 
of Bruel et al., we observed CD303+/Ki-67+ cells in the biopsies 
of HIV-infected subjects (Figures 5A–C) but not in the control 
biopsies (Figures 5D–F). In order to evaluate the specificity of the 
primary antibody, we probed the same biopsies with a matched iso-
type control. An absence of non-specific staining (Figures 5G–I) 
confirmed that the immunoreactivity for CD303 and Ki-67 was 
indeed specific. A minor population of BM-derived pre-pDCs are 
also known to express the myeloid DC marker CD11c. Again, 
consistent with BM-derived pre-pDCs, we observed that most of 
the duodenum-associated pDCs in the HIV biopsies were also 
CD11c+ (Figures 6A–C); however, no CD303+/CD11c+ cells were 
observed in the control biopsies (Figures 6D–F).
FigUre 4 | Duodenum biopsies of hiV/aiDs cases and controls evaluated for coexpression of cD303 (green) and cD123 (red) and for cD303 (green) 
and cD80 (red). Bar represents 20 μm. (a) Control duodenum biopsies probed with a monoclonal FITC-anti-CD303 antibody. (B) Control duodenum biopsies 
probed with a monoclonal PE-anti-CD123 antibody. (c) Control duodenum biopsies DIC image merged with (a,B). (D) HIV case duodenum biopsies probed with a 
monoclonal FITC-anti-CD303 antibody. (e) HIV case duodenum biopsies probed with a monoclonal PE-anti-CD123 antibody. (F) HIV case duodenum biopsies DIC 
image merged with (D,e). (g) Control duodenum biopsies probed with a monoclonal FITC-anti-CD303 antibody. (h) Control duodenum biopsies probed with a 
monoclonal PE-anti-CD80 antibody. (i) Control duodenum biopsies DIC image merged with (g,h). (J) HIV case duodenum biopsies probed with a monoclonal 
FITC-anti-CD303 antibody. (K) HIV case duodenum biopsies probed with a monoclonal PE-anti-CD80 antibody. (l) HIV case duodenum biopsies DIC image 
merged with (J,K).
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gut-associated pDcs in hiV-infected subjects 
Display a Killer-pDc Phenotype
Previous studies have reported that the GI tract experiences sig-
nificant pathology during the course of HIV infection [reviewed 
by Brenchley and Douek (31)]; however, the mechanism of this 
pathology is not fully understood. pDCs have the capacity to 
display a “killer” phenotype, with the ability to lyse target cells 
in either a GZMB- or TRAIL-dependent manner (32, 33). We 
therefore speculated that this may contribute to the gut mucosal 
damage associated with HIV infection. To this end, we probed the 
duodenum biopsies of HIV subjects and controls for coexpression 
of CD303 and GZMB and observed significant immunoreactivity 
FigUre 5 | Duodenum biopsies of hiV/aiDs cases and controls evaluated for coexpression of cD303 (green) and Ki-67 (red). Bar represents 20 μm. 
(a) Control duodenum biopsies probed with a monoclonal FITC-anti-CD303 antibody. (B) Control duodenum biopsies probed with a monoclonal PE-anti-Ki-67 
antibody. (c) Control duodenum biopsies DIC image merged with (D,e). (D) HIV case duodenum biopsies probed with a monoclonal FITC-anti-CD303 antibody. 
(e) HIV case duodenum biopsies probed with a monoclonal PE-anti-Ki-67 antibody. (F) HIV case duodenum biopsies DIC image merged with (a,B). (g) HIV case 
duodenum biopsies probed with a monoclonal FITC-anti-CD303 antibody. (h) HIV case duodenum biopsies probed with a PE-Mouse IgG1,κ isotype control 
antibody. (i) HIV case duodenum biopsies DIC image merged with (g,h).
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(CD303+/GZMB+) in the HIV cohort (Figures  7A–C). In 
contrast, an absence of immunoreactivity with the anti-GZMB 
antibody was observed in control biopsies (Figures  7D–F). It 
has also been reported that GZMB-dependent killer pDCs also 
upregulate the neural adhesion marker CD56; therefore, we addi-
tionally probed the same biopsies with anti-CD56 and observed a 
number of CD303+/CDCD56+ cells in the biopsies of HIV/AIDS 
cases (Figures 8A–C). In contrast, no CD303+/CD56+ cells were 
observed in the controls biopsies (Figures  8D–F). Absence of 
reactivity with matched isotype controls for the anti-GZMB and 
CD56 antibodies suggested that the binding was specific.
Discussion
As the principal source of type I IFN produced by circulating 
immune cells, pDCs play a seminal role in the innate antiviral 
immune response. Under homeostatic conditions, pDCs are 
primarily found in circulation and mucosal tissues such as the 
gastrointestinal lymphoid tissue (GALT) and the respiratory tract 
(34–36). Only small numbers of pDCs are normally present in 
peripheral tissue; however, their transmigration increases sig-
nificantly during inflammation (37, 38). Once activated, pDCs 
have the capacity to release proinflammatory cytokines such as 
CXCL8 and CXCL10, and therefore, they also have the capacity 
to contribute to pathology.
Numerous studies have shown that pDCs are qualitatively 
and quantitatively impacted during HIV infection. For example, 
Malleret et  al. reported a decline in the number of circulating 
pDCs in animals infected with SIV (17). Additionally, Brown 
and coworkers observed a rapid decline in circulating pDCs that 
correlated with their migration to the lymph nodes (19). Other 
studies have reported a decline in circulating pDC numbers in 
HIV cases that inversely correlated with viremia (16, 39, 40).
Several hypotheses have been proposed to explain the decrease 
in circulating pDCs associated with HIV infection, including, 
virus-associated cytopathic effects and pDC redistribution, from 
the circulation into tissue (9, 16, 41–44). Kwa and coworkers 
reported that pDCs infiltrate the colorectal region of the gut in 
FigUre 6 | Duodenum biopsies of hiV/aiDs cases and controls evaluated for coexpression of cD303 (green) and cD11c (red). Bar represents 20 μm. 
(a) HIV case duodenum biopsies probed with a monoclonal FITC-anti-CD303 antibody. (B) HIV case duodenum biopsies probed with monoclonal APC-anti-CD11c 
antibody. (c) HIV case duodenum biopsies DIC image merged with (a,B). (D) Control duodenum biopsies probed with monoclonal FITC-anti-CD303 antibody. 
(e) Control duodenum biopsies probed with monoclonal APC-anti-CD11c antibody. (F) Control duodenum biopsies DIC image merged with (D,e).
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SIV acutely infected rhesus macaques and that the gut infiltrating 
pDCs were producing high levels of IFNα and other proinflam-
matory cytokines (45). Additionally, Reeves et al. reported that 
SIV infection induces the accumulation of pDCs in the gut 
mucosa (23), and Li et al. observed a fourfold increase in pDC 
accumulation in jejunum, colon, and gut-draining LNs of SIV-
infected rhesus macaques (46). Similar distributions of pDCs 
have been observed in HIV cases. For instance, Lehmann and 
coworkers observed increased pDC accumulation in the termi-
nal ileum of HIV-infected subjects (47), and tissue homing was 
explained by significant upregulation of the gut-homing receptor 
CD103, when compared with uninfected controls. These data 
support a model whereby pDCs redistribute from the circulation 
into the gut during the course of HIV infection. Although the 
previous data unequivocally supported this supposition, it was 
recently challenged by the report of Bruel and colleagues whereby 
they described the depletion of IFN-producing pDCs in the 
periphery as a result of activation-driven exhaustion, followed by 
a concomitant increase in gut-associated pDCs (24). They further 
reported that the gut-associated pDCs are primarily naive Ki-67+ 
pDCs, suggesting that the BM-derived pDCs egressed from the 
BM to replace the depleted circulating pDCs and subsequently 
migrate from the periphery to the gut. Therefore, the current 
data suggest that the loss of peripheral pDCs during the course 
of HIV infection is not just a matter of tissue redistribution but 
a combination of pDC depletion, repopulation, and migration.
During the acute infection stage, pDCs respond with a robust 
IFN production; however as the acute stage transitions to the 
chronic stage, they become refractory with respect to their abil-
ity to produce IFN (48). BM-derived pDC precursors have little 
capacity to produce type I IFN and may also have a phenotype dif-
ferent from that of mature circulating pDCs that depends on their 
stage of development (27). Three subsets of pre-pDCs have been 
described based on the expression level of CD34 and HLA-DR 
(Class II) surface markers. All three populations express CD123 
(IL-3α chain receptor); however, CD4 expression is absent in the 
earliest pre-pDCs (Stage I pre-pDCs) but becomes evident in the 
more developed pre-pDCs (Stages II and III) (27). Additionally, 
CD184 (CXCR4) is observed in all three stages. These observa-
tions suggest that pre-pDCs have the capacity to be infected by 
HIV at least as early as Stage II.
In the present study, we observed that duodenum-associated 
CD303+ pDCs expressed Ki-67, but no anti-Ki-67 immunoreac-
tivity was observed in the control biopsies. These observations 
are consistent with those made in SIV-infected cynomologus 
macaques by Bruel et al. (24). Ki-67 is nuclear proliferation anti-
gen, which is expressed by cells in a non-G0 phase of the cell cycle 
and therefore is indicative of pDCs that were recently mobilized 
from the bone marrow (19, 49). Additionally, CD303 is not present 
on Stage I BM-derived pre-pDCs (27); therefore, our data further 
suggests that duodenum-associated pDCs in HIV-infected sub-
jects are largely consistent with Stage II or Stage III pre-pDCs. We 
also observed that gut-associated CD303+ pDCs expressed the B7 
costimulatory molecule CD80. The B7 costimulatory molecule 
CD80 is upregulated during in vitro HIV infection of pDCs (50); 
however, circulating pDCs from healthy or HIV-infected subjects 
show little, if any, CD80 expression. Additionally, characterization 
of pre-pDCs from healthy BM-donors suggests that these cells 
do not express CD80 (27). Our observation of CD80 expression 
by gut-associated pDCs implies that these cells may be activated 
preferentially in the gut over that of those in the circulation. Also, 
in contrast to controls, we observed that gut-associated pDCs in 
HIV-infected subjects express the common myeloid dendritic 
cell protein CD11c. Although murine pDCs express CD11c at 
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low levels, its expression is typically absent on circulating human 
pDCs. Notwithstanding, CD11c expressed on a subpopulation of 
BM-derived pre-pDCs has been described, again supporting the 
supposition that the gut-associated pDCs in our HIV cohort are 
naive BM-derived pDCs.
Activated pDCs have the capacity to express the cytotoxic 
enzyme GZMB; however, its expression is downregulated in the 
presence of IFNα and upregulated by IL-3 (51). Not only are 
BM-derived pre-pDCs refractory to the production of type I IFN, 
we observed gut-associated pDCs in our HIV cohort have low or 
absent CD123 expression, albeit this observation is only qualita-
tive in that it was not practical to quantify this value by IHC. IL-3 
signaling and GZMB expression is intimately connected (51); 
therefore, a dysregulation in CD123 (the IL-3 receptor) may 
potentially impact the expression of GZMB. In addition to the 
cytotoxic and proapoptotic role of GZMB, it also plays a role in 
inflammation and tissue remodeling (50). Severe tissue damage 
leading to increased intestinal epithelium permeability is hallmark 
of HIV infection (52), and this process is not reversed even after 
FigUre 7 | Duodenum biopsies of hiV/aiDs cases and controls evaluated for coexpression of cD303 (green) and granzyme B (gZMB) (red). Bar 
represents 20 μm. (a) HIV case duodenum biopsies probed with a monoclonal FITC-anti-CD303 antibody. (B) HIV case duodenum biopsies probed with 
monoclonal APC-anti-GZMB antibody. (c) HIV case duodenum biopsies DIC image merged with (a,B). (D) Control duodenum biopsies probed with monoclonal 
FITC-anti-CD303 antibody. (e) Control duodenum biopsies probed with monoclonal APC-anti-GZMB antibody. (F) Control duodenum biopsies DIC image merged 
with (D,e). (g) HIV case duodenum biopsies probed with a monoclonal FITC-anti-CD303 antibody. (h) HIV case duodenum biopsies probed with a PE-Mouse IgG1 
isotype control antibody. (i) HIV case duodenum biopsies DIC image merged with (g,h).
long-term HAART therapy (53–55). Although speculative at this 
point, the presence of GZMB may suggest a potential mechanism 
that contributes to the decreased regenerative capacity of the gut 
epithelium and increased mucosal permeability and inflammation 
associated with HIV infection (56–58). To the best of our knowl-
edge, the expression of GZMB and the downregulation of CD123 
in gut-associated pDCs have not been described in HIV; however, 
future studies will be required to fully elucidate the role of GZMB 
in HIV-associated gut pathology. Finally, we observed that most 
CD303+ cells also expressed the neural adhesion molecule CD56. 
Tel et al. have previously described the coexpression of CD303, 
CD56, and GZMB by pDCs activated with the preventative vac-
cine to tick-borne encephalitis virus FSME. These “killer pDCs” 
possessed the tumoricidal capacity to lyse K562 and Daudi cells in 
a contact-dependent manner (59). They additionally reported that 
CD303 and CD56 expression coincided with elevated expression 
of programmed death-ligand 1 (PD-L1), GZMB, and TNF-related 
apoptosis-inducing ligand (TRAIL). It is also noteworthy that all 
pDC neoplasms express the CD56 marker (60), further suggesting 
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that CD56 expression by pDCs is not necessarily novel or without 
precedence. The significance of this marker has yet to be deter-
mined on NK cells so the contribution to pDC biology in the 
context of HIV infection will require further investigations as well.
conclusion
In summary, our data show that subjects with HIV have, on 
average, decreased pDCs in the periphery, when compared with 
healthy controls, consistent with previous reports. Additionally, 
we show that gut-associated pDCs in HIV cases express the 
cellular proliferation marker Ki-67, which suggests that the gut-
associated pDCs are naive and likely of bone marrow origin. 
Finally, we observed that gut-associated pDCs have an activated 
phenotype and also upregulate the proapoptotic enzyme GZMB. 
When taken together, our data support a model of HIV progres-
sion whereby circulating pDCs are depleted and replaced by 
naive BM-derived pDCs, which have little, if any, IFN-producing 
capacity. Ultimately, these pDCs migrate to the gut, potentially 
subjecting the gut mucosa to the inflammatory effects and 
damage associated with inflammatory cytokine production and 
GZMB expression. The type I IFN produced by competent pDCs 
is a critical part of an innate immune response to viral infection. 
Therefore, a greater understanding of the fate of these cells in 
HIV infection may lead to strategies that can restore the IFN-
producing capacity of the innate immune system.
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